

Pelvic Exenteration Surgery: Experience of a Tertiary Cancer Institution in South India

D Suresh Kumar¹, TD Balamurugan², MP Viswanathan³, Navin Noushad⁴

¹Professor and Associate Consultant, Department of Surgical Oncology, Tamilnadu Government Multi Super speciality Hospital, Madras Medical College, Chennai, India 600002

²Post graduate in MCh Surgical Oncology, Department of Surgical Oncology, Tamilnadu Government Multi Super speciality Hospital, Madras Medical College, Chennai, India 600002

³Professor and Senior Consultant, Department of Surgical Oncology, Tamilnadu Government Multi Super speciality Hospital, Madras Medical College, Chennai, India 600002

⁴Assistant Professor and Junior Consultant, Department of Surgical Oncology, Tamilnadu Government Multi Super speciality Hospital, Madras Medical College, Chennai, India 600002

Abstract: Background: Pelvic Exenteration (PE) is an ultra-radical surgical procedure. It is commonly indicated in cases of persistent or recurrent malignancy in the pelvic region post chemoradiation for tumor confined to the central pelvic region with a possible curative intent of R0 resectability. Methods & materials: It is a retrospective study. 27 female patients with advanced pelvic organ malignancies or recurrent carcinoma post chemoradiotherapy (CRT) who underwent treatment at Tamilnadu Government Multi Super Speciality Hospital, Madras Medical College, Chennai were chosen for the study. Later the inoperable cases were excluded from the study and only those who underwent pelvic exenteration surgery (19 cases) were selected and details were collected from the Medical Records Department and analysed. Results: In our study most of the patients were Carcinoma Cervix (63%). Majority of the cases underwent Anterior Pelvic Exenteration (13). All operable cases were found to have very minimal peri-op complications (except one urine leak). Discussion: Our study shows that most common indication for PE was Carcinoma cervix post CRT who underwent Anterior Pelvic Exenteration followed by Ileal Conduit reconstruction and had minimal peri-operative complications. Conclusion: Though Pelvic Exenteration is a very uncommonly done ultra radical procedure, we demonstrated that PEs can be performed safely with minimal complications.

Keywords: Pelvic Exenteration, Perioperative outcomes.

1. Introduction

In this modern era where multimodality treatment and organ restoration are used as treatment for various cancers, Pelvic Exenteration (PE) is a very uncommon ultra-radical surgical procedure. It was primarily performed at Ellis Fischel Cancer Centre and later clearly explained by Brunschwig in 1948 with purely a palliative intent (1). Many studies are going on describing the role of pelvic exenteration as a curative treatment for pelvic or perineal tumors (2). There are three types of PEs – Anterior PE (APE), Posterior PE (PPE), Total PE (TPE). Each type is divided into exenteration phase and reconstruction phase. The exenteration phase targets clear pathologic margins and the reconstructive phase aims to restoration of urinary, faecal diversion with minimal compromise of pelvic floor (3).

It is characterised by the en bloc extirpation of the internal pelvic organs, pelvic peritoneum, regional lymph nodes, anal canal, distal colon and rectum, bladder and inferior ureters (4,5). Persistent and recurrent malignant cases post chemoradiotherapy, tumor confined to central pelvic region with possible resectability to R0 margins are indicated for this Pelvic exenteration (6). The main aim of this study was to assess the peri-operative outcomes in pelvic exenteration surgery in our Institution.

2. Methods & Materials

It is a retrospective study conducted during the period 2015 to 2018. 27 patients who underwent treatment at Tamilnadu Government Multi Super Speciality Hospital, Madras Medical College, Chennai with advanced pelvic organ malignancies or recurrent carcinoma post chemoradiotherapy (CRT) were included for the study. Later the inoperable cases were excluded from the study and only those who underwent pelvic exenteration surgery (19 cases) were selected. The details were collected from the medical records department and analysed.

Operative details: Under General anaesthesia, the patient was placed in lithotomy position. Then the abdomen and peritoneum were cleaned and draped. A midline incision was made and abdomen was opened in layers. A complete exploration of the peritoneal cavity and retroperitoneal spaces was implemented (7). Following this the sigmoid colon and/or ureters were completely mobilized and divided. Then, the organs to be removed were mobilized. For anterior exenterations, it includes the bladder, vagina, uterus or prostate/seminal vesicles cervix and adnexae. For posterior exenterations, it includes the rectosigmoid colon, vagina, uterus cervix and adnexae. Total exenteration removes all of the above mentioned tissues. The appropriate organs were mobilized en-bloc by blunt dissection, clamp-cut-tie sequences and/or electrosurgical devices to relevant vascular supplies and suspensory attachments (8). An elliptical

perineal incision was made and infraflevator resection of the external genitalia and/or anus was undertaken as indicated by diseases extent. Individualized urinary diversion and faecal diversion were then performed.

Reconstruction procedure for the patients who underwent anterior pelvic exenteration was ileal conduit. Posterior pelvic exenteration procedure was followed by sigmoid colostomy. Total pelvic exenteration was followed by wet colostomy(9).

3. Results

Among the total 27 patients, 8 were inoperable. Pelvic side wall fixity intraoperatively was the common indication for inoperability. Inoperable patients were excluded. The peri-operative outcomes of 19 patients in the age group 27 to 75yrs are included in the study. All were female patients. Most of the cases were carcinoma cervix post chemoradiation therapy(53%). The distribution of the cases is shown in Fig: 1. Among them 13 patients underwent Anterior Pelvic Exenteration, 2 patients had Posterior Pelvic Exenteration and 4 patients had Total Pelvic Exenteration(Fig:2). Post-operative complication was noted in one patient(urine leak). The distribution of upfront and recurrent cases included in the study is shown in Fig:3. The duration of the surgery, Per operative blood loss, ICU stay, post-op stay are given in Table:1

Table 1: Mean of per-op and post-op outcomes

SNo	Per,post-operative outcomes	Mean
1.	Surgery duration (120-160mins)	140 mins
2.	Blood loss (120-400ml)	250 ml
3.	ICU stay (2-7days)	3days
4.	Post-op stay(5-31days)	10days
5.	Post-op Complication(urine leak)	1case




Figure 1: Distribution of the sites of cancer




Figure 2: Distribution of the type of surgery performed.




Figure 3: Distribution of the upfront cases and recurrent cases

Thus our study shows that most of the patients were Carcinoma Cervix post Chemoradiotherapy who underwent anterior pelvic exenteration followed by ileal conduit with minimal peri operative complications. No peri-operative mortality was noticed.

4. Discussion

Our hospital is a tertiary referral cancer centre in Chennai, South India, where many malignancies are diagnosed and treated every day. Pelvic exenteration is the only possibly curative intervention for patients with advanced and recurrent pelvic cancers especially recurrent cervical cancer after nonsurgical treatment modalities(Radiotherapy and Chemotherapy)(9). Other conditions are locally advanced bladder and rectal carcinoma(10). Rare indications are primary ovarian cancer in which bladder and rectal resection is needed to achieve free margins for optimal cytoreduction and uterine cancer presenting as locally advanced or recurrent neoplasm in which pelvic irradiation was done as part of the primary treatment and subsequently a radical surgery is necessary for a curative treatment.

Our study included 19 female patients, among which most of them were carcinoma cervix post chemoradiation therapy(53%). Maximum cases underwent anterior pelvic exenteration(13 cases) and remaining cases were PPE(2 cases) and TPE(4 cases). All surgeries were done with minimal peri-operative complications except one(urine leak). The study shows similar results to the study done by Ravi Maharaj et al in 2017. He has made a note of his

experiences in pelvic exenteration surgery done in his institution at Trinidad (11). Pandey et al followed up 48 patients who underwent PE in Cancer Institute (WIA), Chennai during the period 1981 to 2000 and found that for carefully selected locally advanced cancer in the pelvis, pelvic exenteration may provide the opportunity of long survival(12). In a retrospective analysis of 28 patients by Andrea P et al at Brazil during the period 2008 to 2011 postoperative urinary and infectious complications accounted for the common perioperative morbidity(13). Promising results have been reported with preoperative and intraoperative radiotherapy combined with surgical resection of advanced pelvic tumors.

The main purpose of this retrospective study was to analyse peri-operative outcome of pelvic exenteration. We do not report survival analysis, given the lack of follow-up time to date. The major limitations of our study are its retrospective nature of analysis and limited number of patients. Most of the reports based on pelvic exenteration showed such limitations. Till date only one study has analysed surgical and survival outcomes of the procedure. This could be possibly because of the rarity of this procedure.

5. Conclusion

In this age of advancement in treatment approach like multimodality approach and organ preservation for malignancies, pelvic exenteration has become a rarely done procedure. Nevertheless, for carefully selected patients with locally advanced non-metastatic pelvic cancers, it is the only opportunity for long-term survival. While the number of cases in our series limits survival statistics assessment, we demonstrated that Pelvic Exenteration can be performed safely with minimal complications with careful case selection.

6. Conflicts of Interest

Nil

References

- [1] Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. A one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. *Cancer* 1948;1:177-83.
- [2] Hafner GH, Petrelli NJ. Pelvic exenteration for colorectal adenocarcinoma. In Sugarbaker PH editor: "Pelvic Surgery and Treatment for Cancer". Missouri: Mosby 1994:285-96.
- [3] Rodriguez-Bigas MA, Petrelli NJ, Lopez MJ, Petros JG. Modified pelvic exenterations. *Surg Oncol Clin N Am* 1994;3:239-46.
- [4] Brodsky JT, Sloane BB, Khanna OP. Total pelvic exenteration with preservation of fecal continence. *J Surg Oncol* 1993;53:261-4.
- [5] Koda K, Tobe T, Takiguchi N, Oda K, Ito H, Miyazaki M. Pelvic exenteration for advanced colorectal cancer with reconstruction of urinary and sphincter functions. *Br J Surg* 2002;89:1286-9.
- [6] Vezeridis MP, Wanebo HJ. Extended radical pelvic surgery including sacral resection. *Surg Oncol Clin N Am* 1994;3:291-306.
- [7] Yamada K, Ishizawa T, Niwa K, Chuman Y, Aikou T. Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. *Dis Colon Rectum* 2002;45:1078-84.
- [8] Weiss L. Metastatic inefficiency and its surgical implications. In Sugarbaker PH, editor. "Pelvic Surgery and Treatment for Cancer". Missouri: Mosby 1994:13-21.
- [9] Spratt JS, Meyer JS. Biologic considerations with pelvic neoplasms. *J Surg Oncol* 1999;71:198-205.
- [10] Crowe PJ, Temple WJ, Lopez MJ, Ketcham AS. Pelvic exenteration for advanced pelvic malignancy. *Semin Surg Oncol* 1999;17:152-60.
- [11] Ravi M et al Pelvic exenteration case series: a single surgeon's experience at one institution in Trinidad and Tobago. *International journal of surgery case reports*, 34(2017);4-10
- [12] Pandey D, Zaidi S, Mahajan V, Kannan et al. Pelvic exenteration: a perspective from a regional cancer center in India. *Indian journal of Cancer* 2004;41:3.
- [13] Andrea P, William K, et al. Surgical results of pelvic exenteration in the treatment of gynaecological cancer. *World journal of surgical oncology* 2014;12:279.